GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss ...

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

The eMed Population Health digital health platform announced Tuesday that former X Chief Executive Officer Linda Yaccarino ...

After stepping down from X in July, Yaccarino is taking the CEO job at eMed Population Health, which makes a digital health platform for managing GLP-1 weight loss drugs. [Link: eMed® Population ...

The company has launched the ad campaign with three patient ambassadors: Brian, Jeanette and Jennifer, each of whom is ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

Former X CEO and senior NBCUniversal executive Linda Yaccarino has been named CEO of digital weight-loss firm eMed.

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...

A Massachusetts biotech working on a class of medicines called circular RNA therapeutics beat out companies from around the ...

As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...